Clin Obstet Gynecol. 2024 Jun 1;67(2):411-417. doi: 10.1097/GRF.0000000000000857. Epub 2024 Mar 11.
We describe the evolution of treatment recommendations for chronic hypertension (CHTN) in pregnancy, the CHTN and pregnancy (CHAP) trial, and its impact on obstetric practice. The US multicenter CHAP trial showed that antihypertensive treatment for mild CHTN in pregnancy [blood pressures (BP)<160/105 mm Hg] to goal<140/90 mm Hg, primarily with labetalol or nifedipine compared with no treatment unless BP were severe reduced the composite risk of superimposed severe preeclampsia, indicated preterm birth <35 weeks, placental abruption, and fetal/neonatal death. As a result of this trial, professional societies in the United States recommended treatment of patients with CHTN in pregnancy to BP goal<140/90 mm Hg.
我们描述了慢性高血压(CHTN)在妊娠中的治疗建议的演变、CHTN 和妊娠(CHAP)试验及其对产科实践的影响。美国多中心 CHAP 试验表明,对于轻度 CHTN 的妊娠患者(血压<160/105mmHg)进行降压治疗至目标<140/90mmHg,主要使用拉贝洛尔或硝苯地平治疗,除非血压严重升高,否则不进行治疗,这可以降低复合风险,包括重度子痫前期、早产<35 周、胎盘早剥和胎儿/新生儿死亡。由于这项试验,美国的专业协会建议治疗妊娠合并 CHTN 的患者将血压降至<140/90mmHg。